Powdered green tea has antilipogenic effect on Zucker rats fed a high-fat diet

被引:60
作者
Hasegawa, N [1 ]
Yamda, N [1 ]
Mori, M [1 ]
机构
[1] Nagoya Bunri Coll, Dept Food & Nutr, Nishi Ku, Nagoya, Aichi 4510077, Japan
关键词
green tea; Zucker; high-fat diet; triglyceride; lipogenesis; cholesterol;
D O I
10.1002/ptr.1177
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The effect of powdered green tea on the lipid metabolism was studied in male Zucker rats fed a 50% sucrose diet containing 15% butter. The oral treatment of 130 mg powdered green tea per day depressed body weight increase and various adipose tissue weights but food intake was unaffected. The treatment also slightly increased the plasma triglycerides. These effects were likely mediated by the inhibition of lipogenesis in the adipose tissues. The experimental group had a higher concentration of liver total lipid, triglycerides and plasma protein, and lower liver weights than the controls. This may be due to lipid deposition in the liver because of the reduction in adipose tissue weights. It was found that powdered green tea lowered the plasma total cholesterol but liver total cholesterol was unaffected. The results indicate that the hypocholesterolemic activity of powdered green tea might be due to the inhibition of the synthesis of cholesterol in the liver. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:477 / 480
页数:4
相关论文
共 15 条
[1]   Jasmine green tea epicatechins are hypolipidemic in hamsters (Mesocricetus auratus) fed a high fat diet [J].
Chan, PT ;
Fong, WP ;
Cheung, YL ;
Huang, Y ;
Ho, WKK ;
Chen, ZY .
JOURNAL OF NUTRITION, 1999, 129 (06) :1094-1101
[2]  
FOLCH J, 1957, J BIOL CHEM, V226, P497
[3]  
Hasegawa N, 2000, J HEALTH SCI, V46, P153
[4]   Vitamin C is one of the lipolytic substances in green tea [J].
Hasegawa, N ;
Niimi, N ;
Odani, F .
PHYTOTHERAPY RESEARCH, 2002, 16 :S91-S92
[5]   Modulation of endocrine systems and food intake by green tea epigallocatechin gallate [J].
Kao, YH ;
Hiipakka, RA ;
Liao, SS .
ENDOCRINOLOGY, 2000, 141 (03) :980-987
[6]  
KATIYAR SK, 1992, CANCER RES, V52, P6890
[7]  
MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613
[8]  
Noda Y, 1997, BIOCHEM MOL BIOL INT, V42, P35
[9]  
Sayama K, 2000, IN VIVO, V14, P481
[10]  
Uchida S., 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS302, DOI 10.1111/j.1440-1681.1995.tb02928.x